Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2A | Q92830 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12532831 | 1.00 | KAT2A (0.32) | KAT2AALDH1A1USP2POLBMAPT | |
| SCHEMBL13310477 | 0.80 | KAT2A (0.30) | KAT2A | |
| SCHEMBL12532837 | 0.80 | KAT2A (0.30) | KAT2A | |
| SCHEMBL13310475 | 0.80 | KAT2A (0.36) | KAT2APOLB | |
| SCHEMBL13310479 | 0.80 | KAT2A (0.36) | KAT2APOLB | |
| SCHEMBL13434959 | 0.79 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL12532854 | 0.79 | — | — | |
| SCHEMBL13310476 | 0.78 | KAT2A (0.48) | KAT2APOLB | |
| SCHEMBL12532836 | 0.78 | KAT2A (0.48) | KAT2APOLB | |
| SCHEMBL23963273 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194632-A1 | Method for Screening for Compounds Selectively Interacting with RAD9 | MAGNACHEM INTERNATIONAL LABORATORIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194632-A1 | Method for Screening for Compounds Selectively Interacting with RAD9 | MAGNACHEM INTERNATIONAL LABORATORIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8501431-B2 | Method for screening for compounds selectively interacting with RAD9 | MAGNACHEM INTERNATIONAL LABORATORIES, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100137618-A1 | METHOD FOR SCREENING FOR COMPOUNDS SELECTIVELY INTERACTING WITH RAD9 | MAGNACHEM INTERNATIONAL LABORATORIES, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100137618-A1 | METHOD FOR SCREENING FOR COMPOUNDS SELECTIVELY INTERACTING WITH RAD9 | MAGNACHEM INTERNATIONAL LABORATORIES, INC. | 2010-06-03 | — | — | US | disclosed |
| US-7323495-B2 | Synthetic lactone formulations and method of use | MAGNACHEM INTERNATIONAL LABORATORIES, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323495-B2 | Synthetic lactone formulations and method of use | MAGNACHEM INTERNATIONAL LABORATORIES, INC. (US) | 2008-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137618-A1 | METHOD FOR SCREENING FOR COMPOUNDS SELECTIVELY INTERACTING WITH RAD9 | TP53, RPL19, HSPE1 | KAT2A 3351/4885ALDH1A1 1977/4885USP2 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.